The present disclosure generally includes lung cancer, prostate cancer, breast cancer, hepatocellular carcinoma, esophageal cancer, colorectal cancer, pancreatic cancer, bladder cancer, kidney cancer, ovarian cancer, gastric cancer, fibroma, glioma, and melanoma, and The present invention relates to a combination therapy using an inhibitor of transforming growth factor β (TGFβ) and an inhibitor of programmed cell death protein 1 (PD-1) for the treatment of cancer such as metastasis or prevention of recurrence of cancer diseases.本開示は、概して、肺癌、前立腺癌、乳癌、肝細胞癌、食道癌、結腸直腸癌、膵臓癌、膀胱癌、腎臓癌、卵巣癌、胃癌、線維癌、神経膠腫、及び黒色腫、ならびにこれらの転移などの癌の治療または癌疾患の再発予防のための、形質転換成長因子β（ＴＧＦβ）の阻害物質及びプログラム細胞死タンパク質１（ＰＤ－１）の阻害物質を使用する併用療法に関する。
